ASCO 2024 - Henar Hevia and Carolyn Sousa

The future of cancer care is personalisation. New breakthroughs are increasingly highly targeted, with powerful results, but only for patients with particular genetic markers. This means the innovation coming from oncology researchers needs to be matched by similar progress in diagnostics, as well as frameworks that ensure patients have access to those diagnostics.
At ASCO 24, pharmaphorum’s Jonah Comstock caught up with Henar Hevia, therapeutic area lead for oncology at Johnson & Johnson, and Carolyn Sousa, commercial lead for solid tumours at Johnson & Johnson, to talk about the importance of targeted therapies in conditions like EGFR-mutated lung cancer and some of the work J&J is doing in that area.
They talk about the exciting innovations at the conference, from radioligand therapies to bispecific antibodies, and discuss the importance of collaboration for getting patients connected with the right life-changing therapy.
Tune in below for the whole conversation, including more updates on J&J’s oncology research.
Subscribe to the pharmaphorum RUclips channel for in-depth conversations with innovators across healthcare: / @pharmaphorum
Join us on Twitter for the latest news, features, event coverage, and discussions: / pharmaphorum
And for everything, everywhere, all at once, visit our official site: pharmaphorum.com/